Javascript must be enabled for this website to work.

#script { display:none; } #noScript{ width: 350px; height: 175px; text-align: center; background: white; padding: 35px; display: block; margin-top: -87px; top: 50%; position: absolute; border-bottom: 1px solid #c2c2c2; border-left: 1px solid #e6e6e6; border-right: 1px solid #e6e6e6; border-radius: 5px; -webkit-border-radius: 5px; -moz-border-radius: 5px; margin-left: 50%; left: -175px; } #noScript img{width:100%;} body{background:#f7f7f7;}

respiratory

Public Health

New cancer drugs are very expensive – heres how we work out value for our money

By Jonathan Karnon, Hossein Haji Ali Afzali, Laura C Edney

9 Sep 2015

The Senate Standing Committee on Community Affairs is expected to table its report on the “Availability of new, innovative and specialist cancer drugs in Australia” today. Initiated by South Australian senator Nick Xenophon, the inquiry, which was initially slated to report in late March, is focusing on timely access and affordability of cancer drugs, and ...

Already a member?

Enter your email to keep reading.

Not a member yet?

Join now for free, independent news relevant to your specialty. the limbic is intended for practicing health care professionals only.

Title: *

Name: *

Email: *

AHPRA Number: *

Can't remember your AHPRA number? Search for it here

What's your primary area of interest? *

The limbic's weekly newsletter is a round up of key news highlights that's relevant to your specialty. The newsletter may contain advertising and educational or promotional material from carefully selected industry partners including pharmaceutical companies, government and not-for-profit organisations.

You will not receive advertisers only emails and your details will not be shared with any other party.

I would like to receive the limbic newsletter *

I have read and agree to the limbic Terms and Conditions & Privacy Policy *

Cancel

New cancer drugs are very expensive – heres how we work out value for our money

Already a member?

Not a member yet?

New cancer drugs are very expensive – heres how we work out value for our money